Combined fludarabine and rituximab for low grade lymphoma and chronic lymphocytic leukemia

David G. Savage, Neil S. Cohen, Charles S. Hesdorffer, Daniel Heitjan, Martin W. Oster, Thomas J. Garrett, Michael Bar, Salvatore Del Prete, Robert March, Mathew Lonberg, Susan Talbot, J. Gregory Mears, Michael Flamm, Robert N. Taub, Gwen Nichols

Research output: Contribution to journalArticle

Abstract

As both fludarabine and rituximab are active against indolent lymphoproliferative disorders, we have studied the combination of fludarabine and rituximab in patients with low-grade lymphoma and chronic lymphocytic leukemia (CLL) in phase I/II fashion. Of 33 patients enrolled, 21(63.6%) had low-grade lymphoma and 12 (36.4%) had CLL. They received fludarabine 30 mg/m2 on days 1-4 and rituximab 125, 250 or 375 mg/m2 on day 5 at intervals of 28 days to a maximum of 8 cycles. Three patients were removed from the study because of rituximab-associated anaphylaxis and four because of prolonged hematopoietic toxicity. Toxicity and responsiveness did not differ at the different dose levels of rituximab. For 29 evaluable patients, responses were seen in 82.8% and complete responses in 34.5%. Of 7 responding patients not referred for stem cell transplantation, 6 remain in complete remission at a median follow-up of 16 months (range 4-30 months). Of 13 previously untreated patients, all responded and 46.2% had a complete response. Of 16 previously treated patients, 68.5% responded and 25% had a complete response. The combination of fludarabine and rituximab has major activity and acceptable toxicity in patients with low-grade lymphoma and CLL.

Original languageEnglish (US)
Pages (from-to)477-481
Number of pages5
JournalLeukemia and Lymphoma
Volume44
Issue number3
DOIs
StatePublished - Mar 1 2003
Externally publishedYes

Fingerprint

B-Cell Chronic Lymphocytic Leukemia
Non-Hodgkin's Lymphoma
Lymphoproliferative Disorders
fludarabine
Rituximab
Stem Cell Transplantation
Anaphylaxis

Keywords

  • Chronic lymphocytic leukemia
  • Fludarabine
  • Lymphoma
  • Rituximab

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Savage, D. G., Cohen, N. S., Hesdorffer, C. S., Heitjan, D., Oster, M. W., Garrett, T. J., ... Nichols, G. (2003). Combined fludarabine and rituximab for low grade lymphoma and chronic lymphocytic leukemia. Leukemia and Lymphoma, 44(3), 477-481. https://doi.org/10.1080/1042819021000046958

Combined fludarabine and rituximab for low grade lymphoma and chronic lymphocytic leukemia. / Savage, David G.; Cohen, Neil S.; Hesdorffer, Charles S.; Heitjan, Daniel; Oster, Martin W.; Garrett, Thomas J.; Bar, Michael; Del Prete, Salvatore; March, Robert; Lonberg, Mathew; Talbot, Susan; Mears, J. Gregory; Flamm, Michael; Taub, Robert N.; Nichols, Gwen.

In: Leukemia and Lymphoma, Vol. 44, No. 3, 01.03.2003, p. 477-481.

Research output: Contribution to journalArticle

Savage, DG, Cohen, NS, Hesdorffer, CS, Heitjan, D, Oster, MW, Garrett, TJ, Bar, M, Del Prete, S, March, R, Lonberg, M, Talbot, S, Mears, JG, Flamm, M, Taub, RN & Nichols, G 2003, 'Combined fludarabine and rituximab for low grade lymphoma and chronic lymphocytic leukemia', Leukemia and Lymphoma, vol. 44, no. 3, pp. 477-481. https://doi.org/10.1080/1042819021000046958
Savage DG, Cohen NS, Hesdorffer CS, Heitjan D, Oster MW, Garrett TJ et al. Combined fludarabine and rituximab for low grade lymphoma and chronic lymphocytic leukemia. Leukemia and Lymphoma. 2003 Mar 1;44(3):477-481. https://doi.org/10.1080/1042819021000046958
Savage, David G. ; Cohen, Neil S. ; Hesdorffer, Charles S. ; Heitjan, Daniel ; Oster, Martin W. ; Garrett, Thomas J. ; Bar, Michael ; Del Prete, Salvatore ; March, Robert ; Lonberg, Mathew ; Talbot, Susan ; Mears, J. Gregory ; Flamm, Michael ; Taub, Robert N. ; Nichols, Gwen. / Combined fludarabine and rituximab for low grade lymphoma and chronic lymphocytic leukemia. In: Leukemia and Lymphoma. 2003 ; Vol. 44, No. 3. pp. 477-481.
@article{0719d3b3e8ec4fffbcc0c6363c57fe17,
title = "Combined fludarabine and rituximab for low grade lymphoma and chronic lymphocytic leukemia",
abstract = "As both fludarabine and rituximab are active against indolent lymphoproliferative disorders, we have studied the combination of fludarabine and rituximab in patients with low-grade lymphoma and chronic lymphocytic leukemia (CLL) in phase I/II fashion. Of 33 patients enrolled, 21(63.6{\%}) had low-grade lymphoma and 12 (36.4{\%}) had CLL. They received fludarabine 30 mg/m2 on days 1-4 and rituximab 125, 250 or 375 mg/m2 on day 5 at intervals of 28 days to a maximum of 8 cycles. Three patients were removed from the study because of rituximab-associated anaphylaxis and four because of prolonged hematopoietic toxicity. Toxicity and responsiveness did not differ at the different dose levels of rituximab. For 29 evaluable patients, responses were seen in 82.8{\%} and complete responses in 34.5{\%}. Of 7 responding patients not referred for stem cell transplantation, 6 remain in complete remission at a median follow-up of 16 months (range 4-30 months). Of 13 previously untreated patients, all responded and 46.2{\%} had a complete response. Of 16 previously treated patients, 68.5{\%} responded and 25{\%} had a complete response. The combination of fludarabine and rituximab has major activity and acceptable toxicity in patients with low-grade lymphoma and CLL.",
keywords = "Chronic lymphocytic leukemia, Fludarabine, Lymphoma, Rituximab",
author = "Savage, {David G.} and Cohen, {Neil S.} and Hesdorffer, {Charles S.} and Daniel Heitjan and Oster, {Martin W.} and Garrett, {Thomas J.} and Michael Bar and {Del Prete}, Salvatore and Robert March and Mathew Lonberg and Susan Talbot and Mears, {J. Gregory} and Michael Flamm and Taub, {Robert N.} and Gwen Nichols",
year = "2003",
month = "3",
day = "1",
doi = "10.1080/1042819021000046958",
language = "English (US)",
volume = "44",
pages = "477--481",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - Combined fludarabine and rituximab for low grade lymphoma and chronic lymphocytic leukemia

AU - Savage, David G.

AU - Cohen, Neil S.

AU - Hesdorffer, Charles S.

AU - Heitjan, Daniel

AU - Oster, Martin W.

AU - Garrett, Thomas J.

AU - Bar, Michael

AU - Del Prete, Salvatore

AU - March, Robert

AU - Lonberg, Mathew

AU - Talbot, Susan

AU - Mears, J. Gregory

AU - Flamm, Michael

AU - Taub, Robert N.

AU - Nichols, Gwen

PY - 2003/3/1

Y1 - 2003/3/1

N2 - As both fludarabine and rituximab are active against indolent lymphoproliferative disorders, we have studied the combination of fludarabine and rituximab in patients with low-grade lymphoma and chronic lymphocytic leukemia (CLL) in phase I/II fashion. Of 33 patients enrolled, 21(63.6%) had low-grade lymphoma and 12 (36.4%) had CLL. They received fludarabine 30 mg/m2 on days 1-4 and rituximab 125, 250 or 375 mg/m2 on day 5 at intervals of 28 days to a maximum of 8 cycles. Three patients were removed from the study because of rituximab-associated anaphylaxis and four because of prolonged hematopoietic toxicity. Toxicity and responsiveness did not differ at the different dose levels of rituximab. For 29 evaluable patients, responses were seen in 82.8% and complete responses in 34.5%. Of 7 responding patients not referred for stem cell transplantation, 6 remain in complete remission at a median follow-up of 16 months (range 4-30 months). Of 13 previously untreated patients, all responded and 46.2% had a complete response. Of 16 previously treated patients, 68.5% responded and 25% had a complete response. The combination of fludarabine and rituximab has major activity and acceptable toxicity in patients with low-grade lymphoma and CLL.

AB - As both fludarabine and rituximab are active against indolent lymphoproliferative disorders, we have studied the combination of fludarabine and rituximab in patients with low-grade lymphoma and chronic lymphocytic leukemia (CLL) in phase I/II fashion. Of 33 patients enrolled, 21(63.6%) had low-grade lymphoma and 12 (36.4%) had CLL. They received fludarabine 30 mg/m2 on days 1-4 and rituximab 125, 250 or 375 mg/m2 on day 5 at intervals of 28 days to a maximum of 8 cycles. Three patients were removed from the study because of rituximab-associated anaphylaxis and four because of prolonged hematopoietic toxicity. Toxicity and responsiveness did not differ at the different dose levels of rituximab. For 29 evaluable patients, responses were seen in 82.8% and complete responses in 34.5%. Of 7 responding patients not referred for stem cell transplantation, 6 remain in complete remission at a median follow-up of 16 months (range 4-30 months). Of 13 previously untreated patients, all responded and 46.2% had a complete response. Of 16 previously treated patients, 68.5% responded and 25% had a complete response. The combination of fludarabine and rituximab has major activity and acceptable toxicity in patients with low-grade lymphoma and CLL.

KW - Chronic lymphocytic leukemia

KW - Fludarabine

KW - Lymphoma

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=0037347898&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037347898&partnerID=8YFLogxK

U2 - 10.1080/1042819021000046958

DO - 10.1080/1042819021000046958

M3 - Article

C2 - 12688318

AN - SCOPUS:0037347898

VL - 44

SP - 477

EP - 481

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 3

ER -